Empagliflozin mitigates depression-like behavior in diabetic mice via putative CRF1 receptor modulation: behavioral, biochemical and in silico studies
Abstract
Diabetes is one of the main cause and major risk factor for the development of neurodegenerative and neuropsychiatric disorders, including depression, with rising prevalence and increasing co-morbidities worldwide. However, the relationship between diabetes and depression in animal models has not been thoroughly investigated. The present study aimed to investigate the antidepressant potential of empagliflozin (EMPA) in diabetic mice subjected to a chronic unpredictable mild stress (CUMS) model, focusing on its interaction with the corticotropin-releasing factor 1 receptor (CRF1). Initially, diabetes was induced in animals by injection of streptozotocin (STZ) at low dose (35 mg/kg, i.p.), followed by CUMS to provoke depression-like state (1-20 days). EMPA at doses of 5 and 10 mg/kg was administered orally as the test compound, while metformin (MET; 200 mg/kg) and clomipramine (CLMP, 10 mg/kg) alone and in combination (MET + CLMP) were used as standard treatments. All treatments were given once daily for 14 consecutive days (21-35 days). Behavioral assessments were carried out from days 36 to 41, using several paradigms like splash tests, sucrose preference test, open field test, tail suspension test, and forced swim test, respectively. EMPA, particularly at 10 mg/kg, significantly improved behavioral outcomes, indicated by increased distance traveled, higher open-arm entries, reduced immobility time, and shorter grooming latency. Biochemically, EMPA restored antioxidant…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.